Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. 1996

M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
Fondazione A. Cesalpino, Università la Sapienza, Rome, Italy.

BACKGROUND The clinical outcome of hepatitis virus infections is though to depend on the complex interplay between the host immune response profile and virus factors. 90K/MAC-2 BP is a novel member of the Scavenger Receptor Cysteine Rich protein superfamily that functions as a molecular alarm signal for the cellular immune system against both cancer cells and virus infections. METHODS To assess the significance and the potential clinical usefulness of testing for serum levels of 90K/MAC-2 BP in chronic viral hepatitis patients we studied 115 consecutive patients with chronic HCV hepatitis, 28 HBsAg chronic hepatitis patients, 12 asymptomatic HCV carriers and 11 asymptomatic HBV carriers. 103 out of the 115 HCV patients have been treated with recombinant alpha 2a-interferon at the dose of 3 Mega Units (MU) t.i.w. for 6 months followed by 1.5 MU t.i.w. for 6 months, and have been followed up for a further 12 months. Serum levels of 90K/MAC-2 BP were measured by an immunoradiometric assay based on the specific SP-2 monoclonal antibody. CONCLUSIONS Serum 90K/MAC-2 BP levels are increased in chronic viral hepatitis patients, being significantly higher in HCV than in HBV patients. In chronic HCV hepatitis, serum 90K/MAC-2 BP levels are related to both the degree of disease severity and duration of infection. Moreover, elevated 90K/MAC-2 BP serum levels are an independent predictor of failure to respond to alpha-interferon treatment in a cohort of community-acquired chronic hepatitis C patients.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated

Related Publications

M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
March 2000, Journal of clinical immunology,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
September 1994, Clinica chimica acta; international journal of clinical chemistry,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
June 1996, Clinical and experimental immunology,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
January 2008, Immunopharmacology and immunotoxicology,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
February 2023, International journal of molecular sciences,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
January 1992, Archives of virology. Supplementum,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
November 2001, Clinical and experimental immunology,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
January 1992, The Korean journal of internal medicine,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
January 2002, Glycoconjugate journal,
M Artini, and C Natoli, and N Tinari, and A Costanzo, and R Marinelli, and C Balsano, and P Porcari, and D Angelucci, and M D'Egidio, and M Levrero, and S Iacobelli
November 1992, Journal of medical virology,
Copied contents to your clipboard!